ReviewFrontiers in microbiology2026
Gut microbiota-derived tryptophan metabolites in cardiovascular disease: mechanisms, biomarkers, and precision interventions.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota plays a significant role in cardiovascular disease (CVD), through its metabolic products. Tryptophan is a key signaling molecule in the microbiota-host network; its gut microbial metabolites, including indole derivatives, kynurenine and serotonin, have dual effects on cardiovascular homeostasis. This review summarizes research progress on gut microbiota-derived tryptophan metabolites in atherosclerosis, hypertension, heart failure and other CVDs, focusing on metabolic flux in three pathways, the indole, kynurenine (KYN) and 5-hydroxytryptamine (5-HT) pathways, and their mechanisms via gut barrier maintenance, immune regulation through Th17/Treg and aryl hydrocarbon receptor (AhR) axis, and neuroendocrine blood pressure control. It also evaluates clinical evidence for key metabolites, such as indoxyl sulfate (IS), indole-3-propionic acid (IPA) and indole-3-acetic acid (IAA), as novel biomarkers, and explores precision interventions including dietary regimens, probiotic or postbiotic supplementation, traditional Chinese medicine ingredients, and host genetic background-guided strategies. Current evidence shows these metabolites exert both protective and pathogenic effects, highly dependent on disease context, microenvironment and host genetics. However, most data are from animal models and small cohort studies; remaining challenges include detection standardization, causality establishment and clinical translation. Future research should employ large prospective cohorts, multi-omics integration and mechanism-driven intervention trials to systematically elucidate the regulatory network and advance precision prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.